A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02345161 | Completed Phase 3 Results

• 1 other identifier: 116853
• Study Type: interventional
• Target: 1,811
• Locations: 15 countries
• Sites: 159

Brief Summary

This is a phase IIIa, randomised, double-blind, double-dummy, parallel group multicenter study evaluating once daily FF/UMEC/VI (100 microgram \[mcg\]/62.5 mcg/25 mcg) inhalation powder versus twice daily budesonide/formoterol (400 mcg/12 mcg). The primary purpose of this study is to demonstrate improvements in lung function and health status for subjects treated with FF/UMEC/VI compared with budesonide/formoterol for 24 weeks. Once-daily 'closed' triple therapy of a Inhaled Corticosteroid/ Long-acting Muscarinic Receptor Antagonists/ Long Acting Beta-Agonist (ICS/LAMA/LABA) combination FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg) in a single device is being developed with the aim of providing a new treatment option for the management of advanced (GOLD Group D) COPD which will reduce the exacerbation frequency, allow for a reduced burden of polypharmacy, convenience, and increase the potential for improvement in lung function, Health Related Quality of Life (HRQoL) and symptom control over established dual/monotherapies. Subjects meeting all inclusion/exclusion criteria and who have successfully completed all protocol procedures at the Screening Visit will enter the two-week run-in period. Following the run-in period, eligible subjects will be randomised (1:1) to one of the following double-blind treatment groups: FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg via the ELLIPTA™ dry powder inhaler (DPI) once daily in the morning and placebo via reservoir inhaler twice daily OR Budesonide/formoterol 400 mcg/12 mcg via reservoir inhaler twice daily and placebo via the ELLIPTA DPI once daily in the morning. The target enrollment is 1800 randomised subjects at approximately 200 study centers globally. The total duration of subject participation will be approximately 27 weeks, consisting of a 2-week run-in period, 24-week treatment period and a 1-week follow-up period. Subjects will run-in on their existing COPD medications for 2 weeks and in addition will be provided with short acting albuterol/salbutamol to be used on an as-needed basis (rescue medication) throughout the study. Subjects will discontinue all existing COPD medications during the randomised treatment period but may continue their study supplied rescue albuterol/salbutamol. A sub-set of approximately 400 subjects will remain on blinded study treatment for up to a total of 52 weeks to provide additional long term safety data. ELLIPTA and NUBULES are a trade marks of the GlaxoSmithKline Group of Companies. Other company or product names mentioned herein may be the property of their respective owners

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Triple Therapy; Formoterol; Respiratory; COPD; Budesonide; Vilanterol; Fluticasone Furoate; Umeclidinium; Lung Function

Outcome Measures

Primary Outcomes (4)

• Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24

  FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 at Week 24 was defined as the FEV1 values obtained prior to morning dose of the study treatment. Baseline was defined as the value obtained predose (0 minutes) on Day 1. Change from Baseline was calculated as the pre-dose measurement at Week 24 minus the Baseline value. The analysis was performed using a mixed model repeated measures (MMRM) method including covariates of treatment group, smoking status (screening), geographical region, visit, baseline, baseline by visit and treatment by visit interactions. ITT Population comprised of all randomized subjects excluding those who were randomized in error. Only participants with analyzable data at the given time point were analyzed.

  Baseline to Week 24

• Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 52

  FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 at Week 52 was defined as the FEV1 values obtained prior to morning dose of the study treatment. Baseline was defined as the value obtained predose (0 minutes) on Day 1. Change from Baseline was calculated as the pre-dose measurement at Week 24 minus the Baseline value. The analysis was performed using a mixed model repeated measures (MMRM) method including covariates of treatment group, smoking status (screening), geographical region, visit, baseline, baseline by visit and treatment by visit interactions. Extension Population: all participants in the ITT Population who were enrolled into the subset of participants with extension to 52 weeks.

  Baseline to Week 52

• Change From Baseline in St George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease (COPD; SGRQ) Total Score for COPD Participants at Week 24

  The SGRQ-C is a disease-specific questionnaire designed to measure the impact of respiratory disease and its treatment on a COPD participant's health-related quality of life (HRQoL). SGRQ-C total score was converted to SGRQ total score (ranging from 0-100) according to manual. In addition to an overall summary (total) score, scores for the individual domains of Symptoms, Activity, and Impacts (each ranging from 0-100) are produced. A decrease in score indicated improvement in quality of life. The minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Baseline was defined as the value obtained predose on Day 1. Change from Baseline was calculated as total score at Week 24 minus the Baseline value. The analysis for SGRQ total score was performed using a MMRM method including covariates of treatment group, smoking status (screening), geographical region, visit, baseline, baseline by visit and treatment by visit interactions

  Baseline to Week 24

• Change From Baseline in St George's Respiratory Questionnaire-COPD; SGRQ Total Score for COPD Participants at Week 52

  The SGRQ-C is a disease-specific questionnaire designed to measure the impact of respiratory disease and its treatment on a COPD participant's health-related quality of life (HRQoL). SGRQ-C total score was converted to SGRQ total score (ranging from 0-100) according to manual. In addition to an overall summary (total) score, scores for the individual domains of Symptoms, Activity, and Impacts (each ranging from 0-100) are produced. A decrease in score indicated improvement in quality of life. The minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Baseline was defined as the value obtained predose on Day 1. Change from Baseline was calculated as total score at Week 52 minus the Baseline value. The analysis for SGRQ total score was performed using a MMRM method including covariates of treatment group, smoking status (screening), geographical region, visit, baseline, baseline by visit and treatment by visit interactions.

  Baseline to Week 52

Secondary Outcomes (45)

• Transitional Dyspnea Index (TDI) Focal Score Expressed as Least Square Mean at Week 24

  Week 24

• Transitional Dyspnea Index (TDI) Focal Score Expressed as Least Square Mean at Week 52

  Week 52

• Daily Activity Question Percentage of Days Reporting a Score of 2 up to Week 24

  Up to Week 24

• Daily Activity Question Percentage of Days Reporting a Score of 2 up to Week 52

  Up to Week 52

• Mean Annual On-treatment Moderate and/or Severe COPD Exacerbations up to Week 24

  Up to Week 24

Study Arms (2)

FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)

EXPERIMENTAL

Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.

Drug: Triple FF/UMEC/VI; Drug: Placebo to match FF/UMEC/VI; Drug: Albuterol/salbutamol

Budesonide/formoterol (400 mcg/12 mcg)

EXPERIMENTAL

Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.

Drug: Budesonide/Formoterol; Drug: Placebo to match Budesonide/Formoterol combination; Drug: Albuterol/salbutamol

Interventions

Triple FF/UMEC/VI DRUG

The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.

FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)

Placebo to match FF/UMEC/VI DRUG

The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).

FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)

Budesonide/Formoterol DRUG

The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.

Budesonide/formoterol (400 mcg/12 mcg)

Placebo to match Budesonide/Formoterol combination DRUG

The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.

Budesonide/formoterol (400 mcg/12 mcg)

Albuterol/salbutamol DRUG

Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.

Budesonide/formoterol (400 mcg/12 mcg); FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Informed Consent: A signed and dated written informed consent prior to study participation.
• Type of subject: Outpatient.
• Age: Subjects 40 years of age or older at Screening (Visit 1).
• Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, \>45 years, in the absence of hormone replacement therapy. OR Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to safety follow-up contact): Abstinence, Oral Contraceptive, either combined or progestogen alone, Injectable progestogen, Implants of levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device (IUD) or intrauterine system (IUS), Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records.; Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
• COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society.
• Smoking History: Current or former cigarette smokers with a history of cigarette smoking of \>10 pack-years at Screening (Visit 1) \[number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)\]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history.
• Severity of COPD symptoms: A score of \>=10 on the COPD Assessment Test (CAT) at Screening (Visit 1).
• Severity of Disease: Subjects must demonstrate at Screening: \<a post-bronchodilator FEV1 \<50% predicted normal OR a post-bronchodilator FEV1 \<80% predicted normal and a documented history of \>=2 moderate exacerbations or one severe (hospitalized) exacerbation in the previous 12 months. Subjects must also have a measured post albuterol/salbutamol FEV1/FVC ratio of \<0.70 at screening. Note: Percent predicted will be calculated using the European Respiratory Society Global Lung Function Initiative reference equations. Note: A documented history of a COPD exacerbation (e.g., medical record verification) is a medical record of worsening COPD symptoms that required systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnoea, sputum volume, or sputum purulence (colour). Subject verbal reports are not acceptable.
• Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only as required (PRN) COPD medications are not eligible.
• Liver function tests: alanine aminotransferase (ALT) \<2x upper limit of normal (ULN); alkaline phosphatase \<=1.5xULN; bilirubin \<=1.5xULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).

You may not qualify if:

• Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
• Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD). Alpha1-antitrypsin deficiency: Subjects with alpha1-antitrypsin deficiency as the underlying cause of COPD.
• Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.
• Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening.
• Risk Factors for Pneumonia: immune suppression (e.g. Human immunodeficiency virus \[HIV\], Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Subjects at potentially high risk (e.g. very low Body mass index \[BMI\], severely malnourished, or very low FEV1) will only be included at the discretion of the investigator.
• Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded.
• Respiratory tract infection that has not resolved at least 7 days prior to Screening.
• Abnormal Chest X-ray (CXR): Chest X-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a CXR at Screening Visit 1) (or historical radiograph or Computed Tomography \[CT\] scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post pneumonia/exacerbation CXR to be over-read by the central vendor or have a CXR conducted at Screening. For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic CXR will need to be obtained from the Federal Office for Radiation Protection (BfS).
• Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. For subjects taking part in the physical activity monitor subset: Orthopaedic, neurological or other complaints that significantly impair normal biomechanical movement patterns and limit the ability to walk/cycle, as judged by the Investigator.
• Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets entry criteria.
• Unstable or life threatening cardiac disease: subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure
• Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Principal Investigator (PI) will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: Atrial fibrillation (AF) with rapid ventricular rate \>120 Beats Per Minute (BPM); sustained or non-sustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate by Fridericia's formula (QTcF) \>=500 milliseconds (msec) in subjects with QRS \<120 msec and QTcF \>=530 msec in subjects with QRS \>=120 msec.
• Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator, contraindicates study participation.
• Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment.
• Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (159)

GSK Investigational Site

Dimitrovgrad, 6400, Bulgaria

Location

GSK Investigational Site

Lovech, 5500, Bulgaria

Location

GSK Investigational Site

Pleven, 5800, Bulgaria

Location

GSK Investigational Site

Plovdiv, 4002, Bulgaria

Location

GSK Investigational Site

Rousse, 7000, Bulgaria

Location

GSK Investigational Site

Sofia, 1202, Bulgaria

Location

GSK Investigational Site

Sofia, 1407, Bulgaria

Location

GSK Investigational Site

Sofia, 1606, Bulgaria

Location

GSK Investigational Site

Vidin, 3700, Bulgaria

Location

GSK Investigational Site

Guangzhou, Guangdong, 510120, China

Location

GSK Investigational Site

Haikou, Hainan, 570311, China

Location

GSK Investigational Site

Shenyang, Liaoning, 110004, China

Location

GSK Investigational Site

Shenyang, Liaoning, 110015, China

Location

GSK Investigational Site

Hangzhou, Zhejiang, China

Location

GSK Investigational Site

Beijing, 100029, China

Location

GSK Investigational Site

Beijing, 100050, China

Location

GSK Investigational Site

Chongqing, 400037, China

Location

GSK Investigational Site

Wuxi, 214023, China

Location

GSK Investigational Site

Boskovice, 680 01, Czechia

Location

GSK Investigational Site

Brandýs nad Labem, 250 01, Czechia

Location

GSK Investigational Site

Cvikov, 471 54, Czechia

Location

GSK Investigational Site

Karlovy Vary, 360 17, Czechia

Location

GSK Investigational Site

Kralupy nad Vltavou, 278 01, Czechia

Location

GSK Investigational Site

Prague, 140 46, Czechia

Location

GSK Investigational Site

Prague, 169 00, Czechia

Location

GSK Investigational Site

Rokycany, 337 01, Czechia

Location

GSK Investigational Site

Tábor, 390 19, Czechia

Location

GSK Investigational Site

Teplice, 415 10, Czechia

Location

GSK Investigational Site

Haapsalu, 90502, Estonia

Location

GSK Investigational Site

Kohtla-Järve, 31025, Estonia

Location

GSK Investigational Site

Pärnu, 80010, Estonia

Location

GSK Investigational Site

Tallinn, 10117, Estonia

Location

GSK Investigational Site

Tallinn, 10138, Estonia

Location

GSK Investigational Site

Tallinn, 13419, Estonia

Location

GSK Investigational Site

Tallinn, 13619, Estonia

Location

GSK Investigational Site

Tartu, 51014, Estonia

Location

GSK Investigational Site

Elsterwerda, Brandenburg, 04910, Germany

Location

GSK Investigational Site

Frankfurt am Main, Hesse, 60596, Germany

Location

GSK Investigational Site

Neu-Isenburg, Hesse, 63263, Germany

Location

GSK Investigational Site

Wiesbaden, Hesse, 65187, Germany

Location

GSK Investigational Site

Hanover, Lower Saxony, 30159, Germany

Location

GSK Investigational Site

Osnabrück, Lower Saxony, 49074, Germany

Location

GSK Investigational Site

Schwerin, Mecklenburg-Vorpommern, 19055, Germany

Location

GSK Investigational Site

Cologne, North Rhine-Westphalia, 51069, Germany

Location

GSK Investigational Site

Warendorf, North Rhine-Westphalia, 48231, Germany

Location

GSK Investigational Site

Dresden, Saxony, 01069, Germany

Location

GSK Investigational Site

Leipzg, Saxony, 04109, Germany

Location

GSK Investigational Site

Magdeburg, Saxony-Anhalt, 39112, Germany

Location

GSK Investigational Site

Lübeck, Schleswig-Holstein, 23552, Germany

Location

GSK Investigational Site

Berlin, 10717, Germany

Location

GSK Investigational Site

Berlin, 10787, Germany

Location

GSK Investigational Site

Berlin, 12157, Germany

Location

GSK Investigational Site

Hamburg, 20354, Germany

Location

GSK Investigational Site

Athens, 106 76, Greece

Location

GSK Investigational Site

Athens, 115 27, Greece

Location

GSK Investigational Site

Athens, 124 62, Greece

Location

GSK Investigational Site

Athens, 151 26, Greece

Location

GSK Investigational Site

Heraklion, Crete, 71110, Greece

Location

GSK Investigational Site

Kavala, 65500, Greece

Location

GSK Investigational Site

Rethymnon, Crete, 74100, Greece

Location

GSK Investigational Site

Thessaloniki, 56403, Greece

Location

GSK Investigational Site

Thessaloniki, 56429, Greece

Location

GSK Investigational Site

Thessaloniki, 57010, Greece

Location

GSK Investigational Site

Balassagyarmat, 2660, Hungary

Location

GSK Investigational Site

Budaörs, 2040, Hungary

Location

GSK Investigational Site

Debrecen, 4031, Hungary

Location

GSK Investigational Site

Gödöllő, 2100, Hungary

Location

GSK Investigational Site

Hatvan, 3000, Hungary

Location

GSK Investigational Site

Szeged, 6722, Hungary

Location

GSK Investigational Site

Szikszó, 3800, Hungary

Location

GSK Investigational Site

Törökbálint, 2045, Hungary

Location

GSK Investigational Site

Eboli (SA), Campania, 84025, Italy

Location

GSK Investigational Site

Napoli, Campania, 80131, Italy

Location

GSK Investigational Site

Parma, Emilia-Romagna, 43125, Italy

Location

GSK Investigational Site

Milan, Lombardy, 20121, Italy

Location

GSK Investigational Site

Varese, Lombardy, 21100, Italy

Location

GSK Investigational Site

Palermo, Sicily, 90146, Italy

Location

GSK Investigational Site

Pisa, Tuscany, 56124, Italy

Location

GSK Investigational Site

Guadalajara, Jalisco, 44100, Mexico

Location

GSK Investigational Site

Guadalajara, Jalisco, 44500, Mexico

Location

GSK Investigational Site

Zapopan, Jalisco, 45070, Mexico

Location

GSK Investigational Site

Zapopan, Jalisco, 45200, Mexico

Location

GSK Investigational Site

Monterrey, Nuevo León, 64000, Mexico

Location

GSK Investigational Site

Monterrey, Nuevo León, 64020, Mexico

Location

GSK Investigational Site

Monterrey, Nuevo León, 64460, Mexico

Location

GSK Investigational Site

Monterrey, Nuevo León, 64710, Mexico

Location

GSK Investigational Site

Monterrey NL, Nuevo León, 64718, Mexico

Location

GSK Investigational Site

Puebla, Pue, Puebla, 72000, Mexico

Location

GSK Investigational Site

Cuautitlán Izcalli, State of Mexico, 54769, Mexico

Location

GSK Investigational Site

Tlanepantla, State of Mexico, 54055, Mexico

Location

GSK Investigational Site

Chihuahua City, 31238, Mexico

Location

GSK Investigational Site

Mexico City, 07760, Mexico

Location

GSK Investigational Site

Mexico City, 6700, Mexico

Location

GSK Investigational Site

México, 14080, Mexico

Location

GSK Investigational Site

Oaxaca City, 68000, Mexico

Location

GSK Investigational Site

Bialystok, 15-003, Poland

Location

GSK Investigational Site

Bialystok, 15-044, Poland

Location

GSK Investigational Site

Elblag, 82-300, Poland

Location

GSK Investigational Site

Grudziądz, 86-300, Poland

Location

GSK Investigational Site

Ostrowiec Świętokrzyski, 27-400, Poland

Location

GSK Investigational Site

Skierniewice, 96-100, Poland

Location

GSK Investigational Site

Słupsk, 76-200, Poland

Location

GSK Investigational Site

Bucharest, 030303, Romania

Location

GSK Investigational Site

Bucharest, 050159, Romania

Location

GSK Investigational Site

Cluj-Napoca, 400371, Romania

Location

GSK Investigational Site

Codlea, 505100, Romania

Location

GSK Investigational Site

Galati, 800189, Romania

Location

GSK Investigational Site

Piteşti, 110084, Romania

Location

GSK Investigational Site

Suceava, 720284, Romania

Location

GSK Investigational Site

Timișoara, 300310, Romania

Location

GSK Investigational Site

Barnaul, 656 045, Russia

Location

GSK Investigational Site

Izhevsk, 426063, Russia

Location

GSK Investigational Site

Kemerovo, 650000, Russia

Location

GSK Investigational Site

Kemerovo, 650002, Russia

Location

GSK Investigational Site

Moscow, 115409, Russia

Location

GSK Investigational Site

Moscow, 123 182, Russia

Location

GSK Investigational Site

Saint Pertersburg, 196247, Russia

Location

GSK Investigational Site

Saint Petersburg, 194291, Russia

Location

GSK Investigational Site

Saint Petersburg, 198216, Russia

Location

GSK Investigational Site

Saint Petersburg, 198260, Russia

Location

GSK Investigational Site

Saint Petesburg, 195030, Russia

Location

GSK Investigational Site

Saratov, 410028, Russia

Location

GSK Investigational Site

Saratov, 410053, Russia

Location

GSK Investigational Site

Sestroretsk, 197706, Russia

Location

GSK Investigational Site

Stavropol, 355017, Russia

Location

GSK Investigational Site

Tomsk, 634 050, Russia

Location

GSK Investigational Site

Tver', 170036, Russia

Location

GSK Investigational Site

Ufa, 450000, Russia

Location

GSK Investigational Site

Voronezh, 394018, Russia

Location

GSK Investigational Site

Yaroslavl, 150003, Russia

Location

GSK Investigational Site

Yekaterinburg, 620137, Russia

Location

GSK Investigational Site

Bojnice, 972 01, Slovakia

Location

GSK Investigational Site

Levice, 934 01, Slovakia

Location

GSK Investigational Site

Liptovský Hrádok, 033 01, Slovakia

Location

GSK Investigational Site

Poprad, 058 01, Slovakia

Location

GSK Investigational Site

Prešov, 080 01, Slovakia

Location

GSK Investigational Site

Chuncheon, 200-722, South Korea

Location

GSK Investigational Site

Incheon, 403-720, South Korea

Location

GSK Investigational Site

Jeonju-si, Jeollabuk-Do, 561-712, South Korea

Location

GSK Investigational Site

Seoul, 100-032, South Korea

Location

GSK Investigational Site

Seoul, 130-709, South Korea

Location

GSK Investigational Site

Seoul, 138-736, South Korea

Location

GSK Investigational Site

Chernivtsi, 58005, Ukraine

Location

GSK Investigational Site

Dnipropetrovsk, 49074, Ukraine

Location

GSK Investigational Site

Ivano-Frankivsk, 76018, Ukraine

Location

GSK Investigational Site

Kharkiv, 61035, Ukraine

Location

GSK Investigational Site

Kharkiv, 61039, Ukraine

Location

GSK Investigational Site

Kharkiv, 61124, Ukraine

Location

GSK Investigational Site

Kiev, 03680, Ukraine

Location

GSK Investigational Site

Kyiv, 01114, Ukraine

Location

GSK Investigational Site

Kyiv, 02091, Ukraine

Location

GSK Investigational Site

Kyiv, 03038, Ukraine

Location

GSK Investigational Site

Kyiv, 03680, Ukraine

Location

GSK Investigational Site

Kyiv, Ukraine

Location

GSK Investigational Site

Poltava, 36024, Ukraine

Location

GSK Investigational Site

Poltava, 36038, Ukraine

Location

GSK Investigational Site

Ternopil, 46002, Ukraine

Location

GSK Investigational Site

Vinnytsia, 21018, Ukraine

Location

GSK Investigational Site

Vinnytsia, 21029, Ukraine

Location

Related Publications (7)

• Lipson DA, Birk R, Brealey N, Zhu CQ. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study. Adv Ther. 2020 Dec;37(12):4894-4909. doi: 10.1007/s12325-020-01496-7. Epub 2020 Oct 3.

  PMID: 33011864 DERIVED

• Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, Izquierdo Alonso JL, Riesco Miranda JA, Soler-Cataluna JJ, Huerta A, Ismaila AS. Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective. Int J Chron Obstruct Pulmon Dis. 2020 Jul 10;15:1621-1632. doi: 10.2147/COPD.S240556. eCollection 2020.

  PMID: 32764908 DERIVED

• Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2020 Jan;59(1):67-79. doi: 10.1007/s40262-019-00794-w.

  PMID: 31321713 DERIVED

• Naya I, Compton C, Ismaila AS, Birk R, Brealey N, Tabberer M, Zhu CQ, Lipson DA, Criner G. Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Res. 2018 Oct 3;4(4):00047-2018. doi: 10.1183/23120541.00047-2018. eCollection 2018 Oct.

  PMID: 30302335 DERIVED

• Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.

  PMID: 29313286 DERIVED

• Ismaila AS, Birk R, Shah D, Zhang S, Brealey N, Risebrough NA, Tabberer M, Zhu CQ, Lipson DA. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. Adv Ther. 2017 Sep;34(9):2163-2172. doi: 10.1007/s12325-017-0604-x. Epub 2017 Sep 5.

  PMID: 28875459 DERIVED

• Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.

  PMID: 28375647 DERIVED

Related Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Budesonide, Formoterol Fumarate Drug Combination; Albuterol

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Formoterol Fumarate; Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Budesonide; Pregnenediones; Pregnenes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Drug Combinations; Pharmaceutical Preparations; Phenethylamines; Ethylamines

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 19, 2015
• First Posted: January 26, 2015
• Study Start: January 23, 2015
• Primary Completion: April 1, 2016
• Study Completion: April 7, 2016
• Last Updated: July 13, 2018
• Results First Posted: July 13, 2018

Record last verified: 2018-06

Data Sharing

• IPD Sharing: Will share

Locations

RU (21); CN (9); IT (7); HU (8); SL (5); UA (17); ME (17); DE (17); CZ (10); BU (9); GR (10); RO (8); ES (8); KR (6); PL (7)